- FibroBiologics Announces 2024 Annual Meeting of Stockholders
- FibroBiologics Files 2024 First Quarter Report
- FibroBiologics to Present at the BIO International Convention 2024
- FibroBiologics Plans to Collaborate with Charles River to Manufacture Fibroblast-based Spheroids
- FibroBiologics Granted Patent for Regeneration of Cartilage-Type Cells by the Australian Patent Office
- FibroBiologics Presents Data from Dermal Fibroblast Spheroid-based Treatment of Chronic Wounds in a Diabetes Mouse Model at Advanced Wound Care Summit USA
- FibroBiologics Files Patent Application Covering Fibroblast-based Technology for the Potential Treatment of Lupus
More ▼
Key statistics
As of last trade Fibrobiologics Inc (SG0:FRA) traded at 11.10, -9.67% below its 52-week high of 12.29, set on Feb 21, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 11.10 |
---|---|
High | 11.10 |
Low | 11.10 |
Bid | 11.20 |
Offer | 11.60 |
Previous close | 11.30 |
Average volume | 0.00 |
---|---|
Shares outstanding | 32.72m |
Free float | 22.79m |
P/E (TTM) | -- |
Market cap | 398.52m USD |
EPS (TTM) | -1.03 USD |
Data delayed at least 15 minutes, as of Jun 03 2024 07:04 BST.
More ▼